Of particular relevance to our efforts to develop glycosylation-based therapies for chemotherapy-resistant pancreatic cancer, we found that EGFR in SW1990 cells treated with l,3,4-O-Bu3ManNAc experienced an increase in sialylation of 2-fold or higher by using mass spectrometry-based “glycosite”36 and glycan analysis methods similar to those already reported34,37 (relevant experimental data is provided in the Supplemental Materials). This evidence concerns the gene EGFR and familial pancreatic carcinoma.